PolarityTE Inc.

PolarityTE — Investor Presentation (March 2019)

76 slides from PolarityTE's investor presentation, Mar 11, 2019

  1. Slide 1: Regenerates Self

    te - Regenerates ‘Self

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements and projections. The company makes no ‘express or implied representation or warrant as to the completeness of this information or, in the Caseof projections, asto their attainability or the accuracyand completeness of t

  3. Slide 3: ee A

    ee A : - company focused on transforming the lives of patients by = - __ delivering a range of functional therapies using our novel ~~ platform technology att

  4. Slide 4: Name one company or product that truly regenerates anything

    F a Ask yourself—Name one company or product that iY = truly regenerates ANYTHING? 1 4 Tg a ——— “Sse - — ~—S

  5. Slide 5: We Are Often Asked Why We Left Medicine

    We Are Often Asked Why We Left Medicine

  6. Slide 6: The WHY: We Could Do More

    The WHY || We Could Do More = ‘ne GF The Washington Post US experts to help treat burn patients from Taiwan dust explosion President Ma brings expert medical! to offer advice on burns treatment

  7. Slide 7: Science Forgets: Basic Things Matter and Simple Things Work

    Science Forgets: Basic Things Matter and Simple Things Work 4 Complex Simplicity IS Reality ee re 7

  8. Slide 8: PolarityTE: We Design Platform Technologies

    PolarityTE° — We Design Platform Technologies We believe precise design and development of our Core TE Tissue Systems, utilizing novel Minimally Polarized Functional Units (MPFUs), permits us to regenerate a full spectrum of functionally -polarized complex tissues AUTOLOGOUS- FROM THE PATIENT FOR TH

  9. Slide 9: Pipeline Technologies, Platforms & Product Systems

    PolarityTE” || Pipeline Technologies, Platforms & Product Systems Core" TE Tissue Platform Technologias Program Pieters) Opinion & Derelepment Pretelyre Medeing Repisiored4: Commarohly Avdhine eente OnetE Progam Platforms) _Optinizaton & Development Protoiype Modeng lina Develspment Market Cornmurol

  10. Slide 10: Recent Notable Achievements

    i SSS Recent Notable Achievements Accomplished in Preceding 12 Months + Translation of SkinTEfrom Technology to Commercial Product + Rollout of our Strategic and Staged Commercial Launch Process foSkinTE + Hiring of new Chief Commercial Officer and Vice President of Market Access + Build out of Regi

  11. Slide 11: Starting with Skin

    Starting with SKIN

  12. Slide 12: Tissue is NOT Simply Engineered — It Engineers Itself

    Tissue is NOT Simply Engineered — It Engineers Itself | Comparing Skin Substitutes to Actual Skin | Current Commercial Skin Substitutes Skin Dermal Autologous Dermal Allogenic

  13. Slide 13: Understanding the Fundamentals of REAL Skin

    Understanding the Fundamentals of REAL Skin 1s Skin is MUCH More than Keratinocytes Compartment Cells Appendages Function/Responses & Structures Epidermis | keratinocyte predominant) Rete Pegs Protective barrier Melanocyte Pigmentation UVprotection Immunity (antigen presentation) Langerhans cell Con

  14. Slide 14: The Problem with Regenerative Medicine is Tissue Engineering

    The Problem with Regenerative Medicine — is Tissue Engineering Current Com mercial Skin Substitutes The Tissue Engineering Triad Acellular ‘Tissue engineering triads, single cell suspension, growth factors, monolayer cultures and synthetic scaffolds struggle to regenerate complete functional tissues

  15. Slide 15: An Entirely Different Approach to Autologous Skin

    INE An Entirely Different Approach to the neo-generation of Autologous Skin and Patient- Specific Wound Care Acute and Chronic Wounds | aun urnsil Surgical Reconstruction | Scar Revision Skin TE is intended to be used by physicians and other appropriate neevider autologous homologous uses of the ski

  16. Slide 16: SkinTE Simply Put Regenerates Skin

    SkinTE—Simply Put—Regenerates Skin Ms: Skin TE Applied to Complex DFU Woun dl posed Bone and Joint Space | 4 Months of Healing has resulted in the functional loss or absence ofthe skin and integumentary system can use Skin TBas ijunet treatment ahdi/or in place of split-thickness skin grafting, full

  17. Slide 17: SkinTE Simply Put Regenerates Skin

    SkinTE || Simply Put || Regenerates Skin sii Skin TE Applied to Complex Heel De feetl osed Bone, Tendon & Muscle | 12 Weeks of Healing Skin TE is intended to be used by physicians and other appropriate healthcare provi suffered from an event, disease, process or who have an acquired defect that has

  18. Slide 18: SkinTE Simply Put Regenerates Skin

    SkinTE || Simply Put || Regenerates Skin Skin TE is intended to be used by physicians and other appropriate health eare providers for autologous homologous uses ofthe skin and integumentary system. Patients who have suffered from an event, disease, process or who have an acquired defect that has res

  19. Slide 19: Spectrum of Wounds

    @D potartyte = Spectrum of Wounds Acute Wound Initial Wound: The patient suffering from necrotizing fasciitis was left with an open wound with exposed muscle and tendon over his right lower extremity following surgical debridement. Refractory wounds following split-thickness skin grafting were treat

  20. Slide 20: Post-Mohs Reconstruction and Diabetic Foot Ulcer

    Post-Mohs Reconstruction Initial Wound: Following Mohs surgical excision, the patient was left with a full-thickness skin defect with exposed muscle over her philtrum. Due to her history of complications with traditional focal flap reconstruction, the patient elected to utilize SkinTE. Diabetic Foot

  21. Slide 21: APWCA Best Presentation Award

    ADWCA AMERICAN PROFESSIONAL WOUND CARE ASSOCIATION 17" ANNUAL NATIONAL CLINICAL CONFERENCE a a is apwea.org/2018 ] + Stable wound healing + Repigmentation + Formation of sweat and hair follicles + 2-point discrimination intact + “It feels like real skin” — Patient DM. PRESS RELEASE PolarityTE Awarde

  22. Slide 22: SkinTE: Functional Polarization and Hierarchical Organization

    SkinTE™: Functional Polarization and Hierarchical Organization Native Skin Comparative Anatomy QO) Epidermal, dermal and hypodermal compartments Q) A dermal/epidermal junction with rete pegs QO) Appendages (hair follicles, glands) and regenerative structures “OTS. Advanced Skin Substitute Product |

  23. Slide 23: SkinTE vs Native Skin

    SkinTE Native Skin IO eet, NOTE, Comparing SkinTE™ to Native Skin. Comparative of analysis of ancillary histology between SkinTE™ (left) and native skin (right). Ancillary stains include: Hematoxylin and Eosin, Trichrome and Periodic Acid-Schiff. The images and data presented here are from pre-clini

  24. Slide 24: SkinTE Compared to Commercially Available Skin Substitutes

    SkinTE™ Compared to Commercially Available Skin Substitutes Skin is Much More than a Single Layer of Cells Providing a Barrier — Skin is the Largest Organ In The Human Body And Requires Regeneration Of All Components For Normal Function ® Skin “ [Without the component of the recipients own distinct

  25. Slide 25: What is SkinTE?

    What is SkinTE™? For the repair, reconstruction & Teplacement of full-thickness skin SkinTE is a human cellular and tissue-based product derived from a patient’s own skin to regenerate full-thickness, functionally-polarized skin with all of its layers (epidermis, dermis and hypodermis) and appendage

  26. Slide 26: SkinTE: A Simple Approach to Complex Problems

    SkinTE™ || A Simple Approach to Complex Problems "Tae Bott ae sal ful-teknes hn en sample from the patient and return ito PulartyTE inthe provided parcel Patient Overview: Middle-eged male who suffered injuries during a motor vehicle collision to both his left and right lower extremities ‘two years

  27. Slide 27: Progressive Healing, Progressive Sensation & Bio-impedance

    Progressive Healing || Progressive Sensation & Bio-impedance Progressive Healing Through Appendage Development and Propagation Drives Functional Skin Formation Sensation and Bio-Impedance Progression of Healing Following a Single Application of SkinTE* Sequential 12 Week Progress — Representing Earl

  28. Slide 28: We Need More than Great Technologies

    We Need More than Great Technologies Our GOAL || Our CAUSE || Our BELIEF || Our PRIORITY 1. ATotally DIFFERENT and BETTER Technology 2. The EASY Technology for ALL to use 3. LOWER COST and IMPROVING Health Economics 4. SIMPLE Reimbursement that WORKS for All Parties Qranr

  29. Slide 29: SkinTE: Designed and Developed for ALL

    SkinTE || Designed and Developed for ALL f From a small piece of tissue to the regeneration, replacement and/or reconstruction of full -thickness, hair -bearing skin } - Immediate Turnaround of a Patient Specific Tissue Product - No Cost to Stock in Inventory - Simple Dressing Application Following

  30. Slide 30: SkinTE: Waging War on Skin Grafts

    SkinTE™ || Waging War on Skin Grafts SKIN GRAFTS - LIMITED DONOR SKIN NATIVE DONOR SKIN IS LIMITED: Full-thickness autograft skin, which is currently the only way to deliver full-thickness, functional skin to a patient, is extremely limited because it requires closure of the donor site and a patient

  31. Slide 31: SkinTE vs. Skin Grafts: Donor Sites DO Matter

    SkinTE” vs. Skin Grafts—Donor Sites DO Matter | Skin Graft Donor Site @2 years Following Dermatome ) Consider Donor Site(s) Size and Expansion Pain Scar Type of Facility Type of Provider Mark Site } Minimum Actual Size

  32. Slide 32: STSG: Limitations of the Current Standard of Care

    STSG: Limitations of the Current Clinical Standard of Care | Skin grafts are incomplete skin since deeper regenerative cells are left behind at the donor site LIMITATIONS OF THE SKIN GRAFT ae, Kerra Matin While Devoid of Deeper Regenerative Cellular ntiies end Structures [An Incomplete Cutaneous Tis

  33. Slide 33: SkinTE: A Different Way of Healing

    SkinTE™ || A Different Way of Healing Skin Graft Healing Process

  34. Slide 34: Expansion and Growth on the Patient: Human Bioreactor

    Expansion and Growth on the Patient || Human Bioreactor SkinTE™ was designed and developed to treat a full spectrum of defects and conditions of the skin in a manner which truly promotes an d utilizes the concept of self regeneration early on in the healing process - Where Self Regenerates Sel Excis

  35. Slide 35: SkinTE: Replacement of Split-Thickness Skin Grafts

    SkinTE™ || Replacement of Split-Thickness Skin Grafts ative Ski cin TE™ Skin TE Following Rep lacem ent of Split-Thickness Skin Graft in Fibrotic Wound Bed Native Skin Skin TE Conducting Pinch Test of SkinTE at 6 months Dermascope Punch Biopsy of Skin TE Depicts All Layers of Full-Thickness Skin and

  36. Slide 36: SkinTE Biopsy: Correlative Layers of Skin

    SkinTE™ Biopsy || Correlative Layers of Skin Patient Punch Biopsy of SkinTE Depicts All Layers of Full-Thickness Skin Rete Pegs Located at Epidermal/Dermal Junction which Prevent Shear Skin Haematoxylin and Eosin Periodic Acid Schiff Trichrome Blue Stratum Comeum ‘Stratum Lucidum ‘Stratum Granulosm

  37. Slide 37: SkinTE: Coverage of Failed Areas of Skin Grafts

    SkinTE™ || Coverage of Failed Areas of Skin Grafts : Acute Scald Burn to torso, genatialia, thighs in a 2-year-old Areas of failed skin graft treated with Skin TE SkinTE— Progression over 1 Month =z = sats a Welcome to our ine OPINION cee SUMMIT . SkinTE STSG Contraction

  38. Slide 38: Commercialization Updates

    ~ Commercialization Updates | SKINTE’

  39. Slide 39: Planned Commercialization and Staged Growth

    || Planned Commercialization and Staged Growth a —_—_—_—- SkinTE™ — Complete — STAGE 1: Product Development SkinTE product development with the goalofthe easy product to choose and simple product to use Complete © STAGE 2: FDA 361 HCTIP Process Vertfication(s) FDAregulatory processes for verified re

  40. Slide 40: Current Addressable Markets

    Current Addressable Markets | United States Markets ] i : A . : Burn Wounds Relative Wound Incidence Relative Wound Size Relative Market Size 197 Barn Centers — >$3 Billion Addressable Market W Surgical Reconstruction &Traumatic Wounds 600 Level LIII Trauma Centers >$23 Billion Addressable Market /

  41. Slide 41: Commercialization of the SkinTE Tissue Product

    Commercialization of the SkinTE™ Tissue Product 2018 I 400 | 2020 Limited Market Release Deep Product Insight Skin TE Q-Code Polarity Sales Team Covering Entire US Controlled Logistics Market Segmentation Following National Medical Conferences KOL Development _ Multi-Tier System Approach Skin TE Pub

  42. Slide 42: SkinTE: A Comprehensive Approach to Skin Regeneration

    SkinTE™ || AComprehensive Approach to Skin Regeneration Approach From ALL Directions 1. Provider uses materials from the all-inclusive Harvest Box to take a small full-thickness skin sample from the patient and retumitto. SD 4, Provider applies SunTE to patient's ‘wound/defect, covers with dressings

  43. Slide 43: A Totally Different Type of Support

    ee A Totally BOPETST Product | A Totally Different Type of Support 24-Hour Product Support with PolarityTE RTA The PolarityTE Real-Time Assistant (RTA) application is a HIPAA-compliant product support tool to facilitate communication between PolarityTE and providers. } PolarityTE™

  44. Slide 44: Real-Time Assistant App

    PolarityTE® Real-Time Assistant App : . PolarityTE A face-to-face consultation with a " RTA PolarityTE® physician 24 hours a day. A New Way to Communicate and Use PolarityTE® Products: The PolarityTE® Real-Time Assistant App for iOS, And to-Peer Support Between Medical Professionals and PolarityTE °

  45. Slide 45: Reimbursement for SkinTE: Keep it Simple

    Reimbursement for SkinTE || Keep it Simple —— Nese fe Access to the product sparking a paradigm shift SkinTE is available for patients who have functional loss or void of skin/ ™ - integument systems. SkinTE can be used as an adjunct and/or in place of in | skin grafting, temporizing skin coverage a

  46. Slide 46: Next Platform Product on the Horizon

    Next Platform Product on the Horizon 46

  47. Slide 47: OsteoTE

    ( Pre-Treatment I( Post Osteo TE ] & g Welcome to the Shift® g é & Registered December 2018 8 ny q 3 a on S SI o os OsteoTE™ is an autologous - from the patient, for the patient ~ product eg intended for bone repair, and regeneration, including in the long bone, craniomaxillofacial, spine, pot ori t

  48. Slide 48: Defect-Native (Gross) and (CT)

    Defect-Native (Gross) ject Native (CT) Te: Fae ce, \\ eS * model system at timepoint T’%. (b.) Gross image of surgically-created, complete, bi-parietal critical sized defects of both the left and right parietal bones within the in vivo model system at timepoint T°. (c.) 3-D micro-CT of surgically-cr

  49. Slide 49: Pola Interfaces Drive Vascularized Osteogenesis

    Pola Interfaces Drive Vascularized Osteogenesis Comparing OsteoTE™ to Native Bone and Other Products OsteoTE |, OsteoTE+BGM° OsteoTE +DGM'° Autologous Bone Plate. DBM +BI ae BAN ag 5 Auto Bone Plate Defect Control Native Bone DBM + BMP2 OsteoTE + DG“° OsteoTE + Bate OsteoTE

  50. Slide 50: Integrative Angiogenesis and Osteogenesis

    Integrative Angiogenesis and Osteogenesis Correlate this with Functional Outcomes and Tissue Fingerprints } Load (N) Angiogenesis Profile i OsteoTE +BG OsteoTE +06 |, OsteoTE ‘ Native Bone ne Auto Bone Flap see Defect Control L—— DBM +BMP2 oO Os q 15 | Displacement (mm) Osteogenesis Profile } i i i

  51. Slide 51: OsteoTE Preclinical Completed

    Autologous Bone Graft DBM + BMP2 AHBC Autologous DBM+ Bone Graft BMP2 OsteoTE Preclinical Completed CMF [ Long Bone i Spinal Fusion [ olarityTE re Seff Regenerates Sef 51

  52. Slide 52: YES - WE ARE DIFFERENT

    ee alasyale || YES - WE ARE DIFFERENT = 2S. = cece eee PolarityTE & Paradoxical Innovation | ly Innovation is NOT Always What is Asked For A Different Technology, Team, View, Approach and Cause We Know We Are Different and We Take Pride in This P Ra aesairas . THEY WOULD HAVE SAID: FASTER HORSES...”

  53. Slide 53: The PolarityTEAM: Management

    Denver Lough, MD, PhD Ghief Executive Officer & Chairman Chief RED Officer JohnsHopkins Hospitel & School of Medicin Nikolai Sopko, MD, PhD. Chief Scientific Officer & VP R&D. John Hopkins Hospital & School of Medicine Caroline Garrett, DVM, DACLAM Chief Veterinary Officer Johns Hopkins Hospital & S

  54. Slide 54: The PolarityTEAM: Board of Directors

    The PolarityTEAM: Board of Directors Minnie Baylor -Henry Pharm.D., JD | Director * Former Johnson & Johnson VP Worldwide Regulatory Affairs; Deloitte National Director \ Regulatory Affairs Life Sciences. + Former FDA Director/Branch Chief — Division of Drug Marketing, Advertising and Communications

  55. Slide 55: aa, j : i oe ; Chair and Professor

    aa, j : i oe ; Chair and Professor stem cert laa ; i ; ce Department of Surgery Associate Professor j j uesty Rayne). Chief of Oral Dentistry, St. J 4 [ ol bs, MD, PHD, it A get e ‘Grant, m0, Ryan Kate, MD 4 oiriclogyondjoncdony, Winer ef ay Pi Su Attending ShBeen, Curtis Nodanl Hand Fe, sobris Hopk

  56. Slide 56: PolarityTE Corporate and Investor Relations

    Polarity TE Co rporate Polarity TE® Investors Relations Website: www.PolarityTE.com Rich Haerle MBA, MPH ‘Email: Paradigm Shift @Polarity TE.com VP of Investor Relations p= Corporate Inquiries: (800) 378-2694 IR Inquiries: 385) 237-5786 = CorporateInquiries@Polarity TE.com Email: ir@Polarity TE.com

  57. Slide 57: Appendix Slides

    Appendix Slides Preveriyre

  58. Slide 58: Polarity definition

    Question: vain Has Been -_— s Polarit po-laristy: the asymmetric organization of cellular elements, which allows development of specialized tissue and downstream function.

  59. Slide 59: Full-Thickness SkinTE vs. Skin

    Tissue Native Skin a - Full-Thickness SkinTE vs. Skin The functional polarization of SkinTE is designed to regenerate full-thickness, hair -bearing skin with all of the appendages (ha _ ir follicle, glands, etc.) and layered interfaces (epidermis, dermis and hypodermis). We believe the subsequent fu

  60. Slide 60: Polarity Drives Hierarchical Tissue Formation

    Polarity Drives Hierarchical Tissue Formation

  61. Slide 61: The SkinTE Difference: Skin Regenerates Skin

    | The SkinTE™ Difference Simply Put—Skin Regenerates Skin € Embracing Complex Simplicity While other conventional regenerative ‘medicine, cell therapy and tissue engineering companies and products try to reconstruct utes from a variety of cals, isin order to substitute biological processes and inter

  62. Slide 62: Full-Thickness Wounds

    ness Wounds

  63. Slide 63: Comparing the Clinical Standard of Care to SkinTE

    Comparing the Clinical Standard of Care to SkinTE™ Native Scar Healed Wound Native Skin Allograft Margin _Native Skin , Neo, Full-Thickness Allograft ‘Autdgraft |\\ Margin Native Skin Skin defects heal through a process of wound u contraction and often scar formation. While skin 4 grafts reduce cont

  64. Slide 64: SkinTE: Mid-Stage Intelligent and Dynamic Healing

    | SkinTE™- Mid-Stage Intelligent and Dynamic Healing ‘Marginal Contraction and migration Epithet nhigration Columns ‘id Stage SHINTE™ Intogrative Convergence with Native Skin A EZR GREG A be i Native Healed and Contracted Wound \ ~ Psoudo-epithelium Covering the Undertying Sear SkinTE™ Regenerative

  65. Slide 65: Why Does Healing from the Inside Out Matter?

    ® Why Does Healing from the | Inside Out Matter?

  66. Slide 66: Native Tissues: Directionality (Polarity) of Substrate

    Native Tissues- Direesbariaitty (Polarity) of Substrate ‘Specimen Direction ©) Dispersion () Amount GoF Native Skin =1208 16.28 om 097 0.045 0.040 0.035 0.030 Foon i foam 0015 oom 0.005 0.000 -30 0 Direction ) 30

  67. Slide 67: SkinTE: Directionality (Polarity) of Substrate

    SkinTE™- see ene (Polarity) of Substrate Specimen _Direction(°) Dispersion(°) Amount _GoF SkinTE 8.43 19.75 0.67 0.97 0.030 » 0.025 4 st -90 -70 -50 -30 -10 10 30 50 70 90" Direction (9)

  68. Slide 68: Directionality (Polarity) of Substrate

    sues- Direstonsiity (Polarity) of Substrate Specimen Direction(°) Dispersion (°)_ Amount GoF Native Skin _-12.03 16.28 0.70 097 0.045 0.040 0.035 0.030 ¥ 0.025 4 ° & 0.020 0.015 0.010 0.005 - 0.000 4 90 -70 -50 -30 -10 10 30 50 70 Direction (°) Specimen _Direction(°) Dispersion(°)_ Amount _GoF SkinT

  69. Slide 69: Wound-A Directionality

    Specimen _Direction(°) Dispersion (°)__ Amount Wound-A__17.39) 26.94 0.51 0.020 0.015 + 0.010 + ar 0.005 + | 0.000 -# 90 70 50 30 -10 10 30 50 Direction (°) Ae

  70. Slide 70: Direction (°) Dispersion(°) Amount __GoF

    Direction (°) Dispersion(°) Amount __GoF 21,79 0.70 0.97 Amount | | -70 50 - . ~ i 30-10 10 30 50 70 Direction (°)

  71. Slide 71: Wound-B Directionality (Polarity) of Substrate

    Wound-B [Comp Treatment): Directionality (Polarity) of Substrate Specimen Direction (°) Dispersion(*) Amount GoF Wound-A 17.39 26.94 0.56 0.020 0.000 -Hu -- -50 -30 0.51 -10 10 Direction (°) 30 Specimen Direction (°) Dispersion(°) Amount GoF Wound-B 1.97 21.79 0.70 0.97 0.025 0.020 0.015 0.010 Amoun

  72. Slide 72: Native Skin: Ancillary H&E and HD Feature Extraction

    Native Skin - Ancillary H&E and HD Feature Extraction

  73. Slide 73: Native Skin

    Native Skin a

  74. Slide 74: Wound-A

  75. Slide 75: Wound-B

  76. Slide 76: SkinTE

    SkinTE™ ,

PolarityTE — Investor Presentation (March 2019) on 6ix